The list of targeted therapies is rapidly expanding, and molecular tests are already mandatory to guide treatment decisions for patients with metastatic colorectal carcinomas with EGFR antibodies [1,2], lung carcinomas with EGFR inhibitors [3] and metastatic melanomas with BRAF inhibitors [4]. The gene discussed is EGFR; the disease is metastatic melanoma.